T-cell type acute leukaemia+1
RecruitingStudy on the Safety and Effectiveness of OC-1 Therapy for Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma
Study on the Safety and Effectiveness of OC-1 Therapy for Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma
- Disease:T-cell type acute leukaemiaPrecursor T-lymphoblastic lymphoma/leukaemia recurrent
- Substances:OC-1
Spain- Participants:0–17 years · 18–64 years · 65+ years
- Substances:OC-1
- Sponsor:Onechain Immunotherapeutics S.L.











